Organon and Samsung Bioepis Launch Hadlima (biosimilar, adalimumab)
Shots:
- The companies launched Humira biosimilar Hadlima in the US with a list price i.e., an 85% discount off the reference Humira for patients suffering from chronic autoimmune diseases. Hadlima is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL)
- The companies continue to work with partners and other stakeholders to provide wider availability in the US & offer a new comprehensive patient support program “HADLIMA For You” that features educational resources incl. a co-pay program and dedicated nurse coaches
- Samsung Bioepis’s adalimumab biosimilar (marketed under different brand names outside of the US) has been available in 24 markets globally
Ref: Organon | Image: Organon
Related News:- Samsung Bioepis and Organon’s Hadlima (biosimilar, adalimumab) Receive the US FDA’s Approval for Chronic Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
